Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study

Mina Dehghani, Taylor Dear, Anthony Quint, Martha L Louzada, Selay Lam, Chai Wye Phua, Joy Mangel, Kang Howson-Jan, Michael J. Kovacs, Alejandro lazo-Langer, Anargyros Xenocostas, Cyrus C. Hsia

Blood (2021) 138 (Supplement 1): 4682.

https://doi.org/10.1182/blood-2021-153719

Published: 2021

Journal Articles

Effect of Levofloxacin Prophylaxis on Rates of Febrile Neutropenia in Patients Receiving DA-EPOCH-R Chemotherapy for Aggressive Lymphomas

Brent Alexander Parker, Mina Dehghani, Selay Lam, Chai Wye Phua, Cheryl Foster, Kang Howson-Jan, Joy Mangel

Blood (2021) 138 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2021-151885

Published: 2021

Journal Articles

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Eri Kawata, MDPhD, Benjamin Hedley, PhD, Benjamin Chin-Yee, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MDMSc, Cyrus C. Hsia, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Ping Yang, PhD DABMGG, Michael Levy, PhD, Stephanie Santos, Chris Howlett, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138667

Published: 2020

Journal Articles

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Selay Lam, MDBSc,FRCPC, Chai Wye Phua, MD FRCPC, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Brandon Dorland, NP, MSN, Karen Atkinson, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139635

Published: 2020

Journal Articles

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MD MSc, Kang Howson-Jan, MD FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Benjamin Hedley, PhD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3438.

https://doi.org/10.1182/blood-2019-128507

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia

Alejandro Garcia-Horton, MD, Rosanne St. Bernard, MD, Alejandro Lazo-Langner, MD MSc, Anargyros Xenocostas, MD, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Selay Lam, MDBSc, FRCPC, Cyrus C. Hsia, MDBSc, FRCPC

Blood (2018) 132 (Supplement 1): 5560.

https://doi.org/10.1182/blood-2018-99-120129

Published: 2018

Journal Articles

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

Matthew Kang, BHSc, MD FRCPC, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MD MSc, Ian H. Chin-Yee, MD FRCPC, Kang Howson-Jan, MD, Maisam Abouzeenni, BHSc, Michael J. Kovacs, MD FRCPC, Cyrus C. Hsia, BSc, MD FRCPC

Blood (2014) 124 (21): 5527.

https://doi.org/10.1182/blood.V124.21.5527.5527

Published: 2014

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies

Blood (2013) 122 (21): 709.

https://doi.org/10.1182/blood.V122.21.709.709

Published: 2013

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Rachel MA Kyle, BSc, Alejandro Lazo-Langner, MD, MSc, Anargyros Xenocostas, MD, FRCPC, Ian H. Chin-Yee, MD, FRCPC, Kang Howson-Jan, MD, David Sanford, MD, Cyrus C. Hsia, BSc, MD, FRCPC

Blood (2012) 120 (21): 4274.

https://doi.org/10.1182/blood.V120.21.4274.4274

Published: 2012

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients.

Joseph Brandwein, MD, Jeannine Kassis, MD, Brian Leber, MD, Kang Howson-Jan, MD, Mark D. Minden, MD, Andre Galarneau, Jean-Francois Pouliot, PhD

Blood (2011) 118 (21): 422.

https://doi.org/10.1182/blood.V118.21.422.422

Published: 2011

Journal Articles

Predictors of Unsuccessful Mobilization with Granulocyte-Colony Stimulating Factor (G-CSF) Alone In Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell (AHSCT) Transplant

Signy Chow, MD, D. George Ormond, BSc, Alejandro Lazo-Langner, MD, MSC, Kang Howson-Jan, MD, Anargyros Xenocostas, MD, FRCPC

Blood (2010) 116 (21): 4445.

https://doi.org/10.1182/blood.V116.21.4445.4445

Published: 2010

Journal Articles

Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level

Joseph Brandwein, MD, Jeannine Kassis, MD, Brian Leber, MD, Kang Howson-Jan, MD, Mark D. Minden, MD, PhD, Kim Greaves, BSc, RN, DESS, Jean-Francois Pouliot, PhD

Blood (2010) 116 (21): 3985.

https://doi.org/10.1182/blood.V116.21.3985.3985

Published: 2010

Journal Articles

Treatment of Hodgkin Lymphoma without G-CSF Does Not Increase the Risk of Febrile Neutropenia.

Leonard A. Minuk, MD, FRCPC, Ian Chin-Yee, MD, FRCPC, Kang Howson-Jan, MD, FRCPC, Reinhard Lohmann, MD, FRCPC, Alejandro Lazo-Langner, MD MSC, Vinai C. Bhagirath, MD, Joy Mangel, MD, FRCPC

Blood (2009) 114 (22): 2502.

https://doi.org/10.1182/blood.V114.22.2502.2502

Published: 2009

Journal Articles

A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over.

Joseph M. Brandwein, MD, Brian F. Leber, MD, Kang Howson-Jan, MD, Aaron D. Schimmer, MD, PhD, Andre C. Schuh, MD, Vikas Gupta, MD, Karen W.L. Yee, MD, Mark D. Minden, MD, PhD

Blood (2007) 110 (11): 899.

https://doi.org/10.1182/blood.V110.11.899.899

Published: 2007

Journal Articles

Screening for Leptomeningeal Disease by High-Sensitivity Flow Cytometry in High Risk Patients with Aggressive Non-Hodgkin’s Lymphoma.

Joy Mangel, Jazmin Marlinga, Mike Keeney, Jan Popma, Anargyros Xenocostas, Kang Howson-Jan, Kamilia Rizkalla, Ian Chin-Yee

Blood (2007) 110 (11): 4397.

https://doi.org/10.1182/blood.V110.11.4397.4397

Published: 2007

Journal Articles

Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.

A. Keith Stewart, Christine Chen, Kang Howson-Jan, Darrell White, Jean Roy, Michael J. Kovacs, Chaim Shustik, Anna Sadura, Shepherd Lois, Keyue Ding, Ralph Melbourne Meyer, Andrew Belch

Blood (2004) 104 (11): 335.

https://doi.org/10.1182/blood.V104.11.335.335

Published: 2004

NARROW

Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study

Effect of Levofloxacin Prophylaxis on Rates of Febrile Neutropenia in Patients Receiving DA-EPOCH-R Chemotherapy for Aggressive Lymphomas

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients.

Predictors of Unsuccessful Mobilization with Granulocyte-Colony Stimulating Factor (G-CSF) Alone In Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell (AHSCT) Transplant

Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level

Treatment of Hodgkin Lymphoma without G-CSF Does Not Increase the Risk of Febrile Neutropenia.

A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over.

Screening for Leptomeningeal Disease by High-Sensitivity Flow Cytometry in High Risk Patients with Aggressive Non-Hodgkin’s Lymphoma.

Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only